Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsAuthored by Nathan Reiff. Posted: 3/12/2026. 
Quick Look - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicines market is expected to surge to $366 billion over the next eight years. Companies often take a niche approach, developing therapies that target specific cancer types with dedicated mechanisms. Fortunately, several promising treatments have shown substantial potential—and with that comes the possibility of significant sales. Two smaller biotech companies are enjoying notable share-price momentum thanks to their leading oncology medicines. Beyond offering potent treatment potential, these drugs could help the firms transition from unstable or penny-stock status toward greater stability and, potentially, long-term profitability. In both cases, significant challenges remain, making these typical biotech opportunities: high-risk investments that also have the potential to deliver outsized returns for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% during a week when the S&P 500 slipped roughly 1%. That jump added to IOVA's strong year-to-date performance, which has more than doubled the stock's price so far. Still, with a consensus price target of $8.88, Wall Street expects further upside—about 71% from current levels, according to that target. The main catalyst for Iovance's rally is Amtagvi, a T-cell immunotherapy for certain forms of melanoma. Amtagvi was approved in the United States in 2024 and has been gaining momentum in sales and regulatory interest, with additional approvals possible in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could exceed $1 billion in peak U.S. sales. Amtagvi's potential extends beyond melanoma: the drug received Fast Track Designation from the FDA for non–small cell lung cancer and may be effective against other tumor types as well. Some of Iovance's outperformance this year followed its Q4 2025 earnings report, issued in late February, in which the company reported smaller-than-expected losses per share and $5 million in revenue. For the full year, revenue rose roughly 30% year over year. Iovance is a relatively small biotech (around $2 billion in market value) and is often treated like a penny stock by some investors. Analysts remain cautious: about half of its roughly a dozen ratings are Hold or Sell. Risks are elevated—beyond the usual caveats for smaller biotech firms, Iovance's manufacturing model for Amtagvi is a vulnerability. The therapy is personalized, expensive, and complex to produce, which could constrain profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its year-to-date performance far outpaces Iovance's. IBRX shares are up nearly 300% in 2026 alone, and analysts remain optimistic: the average price target is $13.60, roughly 70% above the stock's current level even after the recent run-up. ImmunityBio's primary growth driver is Anktiva, a treatment for certain types of bladder cancer. In February, shares jumped after the European regulator granted the drug conditional marketing authorization—the latest in a string of global approvals. Anktiva has been driving the company's revenue: it generated $113 million in sales last year, about a 700% year-over-year increase. Like Amtagvi, Anktiva may have potential in other cancer indications, and ImmunityBio is actively exploring additional designations. Despite the dramatic share gains over recent quarters, IBRX remains speculative and risky. The company reported a full-year net loss of $351 million for 2025 as research-and-development expenses continued to mount. Wall Street analysts are comparatively bullish on ImmunityBio: six of seven coverage ratings currently recommend Buy or an equivalent. Both Iovance and ImmunityBio illustrate the classic biotech trade-off: compelling clinical and commercial potential paired with substantial execution and financial risks. For investors, these stocks may offer attractive upside, but they also carry the possibility of significant volatility and setbacks—appropriate only for those who understand and accept the risks.
| 
